Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment

FDA clearance for Lucid-MS phase 2 advances Quantum BioPharma’s MS program and underscores its economic stake in UNBUZZD-related royalties.

Rhea-AI Summary

Quantum BioPharma (QNTM) has received FDA clearance to begin a phase 2 clinical trial of Lucid-MS, a patented, first-in-class multiple sclerosis drug candidate focused on protecting and potentially repairing the myelin sheath rather than modulating the immune system.

The company states this will be the first time a drug using this specific mechanism is tested in people living with MS, and notes that the milestone has already attracted a new buy rating from Wall Street analysts. Lucid-MS, developed via subsidiary Lucid Psycheceuticals, has shown prevention and reversal of myelin degradation in preclinical models. Quantum also highlights economic interests in UNBUZZD(TM), retaining 19.84% ownership in Unbuzzd Wellness and a royalty on unbuzzd(TM) sales, starting at 7% until cumulative payments reach $250 million, then 3% in perpetuity.

Positive

• FDA clearance to begin phase 2 trial of Lucid-MS in MS patients
• Lucid-MS preclinical data show prevention and reversal of myelin degradation
• Quantum holds 19.84% ownership of Unbuzzd Wellness as of March 31, 2026
• Royalty on unbuzzd(TM) sales: 7% until $250 million paid, then 3% in perpetuity

Negative

• None.

Argus 15 min delay

+9.42% vs previous close $3.60 last price 3.2x rel. volume Open Argus

Details

Market reaction after Phase 2 FDA clearance: QNTM +9.42%

$3.17 $3.70 Day Range

$151 Market Cap

Following this news, QNTM has gained 9.42%, reflecting a notable positive market reaction. Our momentum scanner has triggered 4 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $3.60. Trading volume is very high at 3.2x the average, suggesting strong buying interest.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

Aug 10 and Aug 14 records described the same FDA clearance, with 24-hour reactions of 0.29% and 17.6...

Analysis

Aug 10 and Aug 14 records described the same FDA clearance, with 24-hour reactions of 0.29% and 17.65%, respectively. The current article restated an already disclosed Phase 2 milestone rather than introducing trial results.

Key Figures

Trial Phase: Phase 2 trial Unbuzzd Ownership: 19.84% Royalty Rate: 7% of sales +2 more

Trial Phase

Phase 2 trial

Lucid-MS in multiple sclerosis

Unbuzzd Ownership

19.84%

Quantum ownership as of March 31, 2026

Royalty Rate

7% of sales

Unbuzzd agreement until payments total $250 million

Royalty Threshold

$250 million

Cumulative payments to Quantum under the Unbuzzd agreement

Perpetual Royalty Rate

3%

Rate after cumulative payments reach $250 million

Historical Context

3 past events · Latest: Aug 10

3 events

1. Aug 10

   FDA Phase 2 clearance

   24h Move

   +0.3%

   FDA clearance enabled randomized, placebo-controlled Phase 2 Lucid-MS trial in progressive MS

2. Aug 14

   FDA Phase 2 clearance

   24h Move

   +17.6%

   FDA approval enabled a pivotal Phase 2 Lucid-MS trial after stronger reported liquidity

3. Jun 02

   FDA clinical hold

   24h Move

   +0.0%

   FDA clinical hold paused Lucid-MS Phase 2 plans pending additional information

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

fda clearance, phase 2 trial, myelin sheath, new chemical entity

4 terms

fda clearance regulatory

"has received FDA clearance to begin a phase 2 trial"

FDA clearance is the U.S. Food and Drug Administration’s official permission to market certain medical devices or diagnostic tests after reviewing evidence that they are as safe and effective as similar products already on the market. For investors, it’s like a product passing a required safety inspection — it reduces regulatory uncertainty, speeds commercial rollout, and can directly affect sales prospects, valuation, and partnership opportunities.

phase 2 trial medical

"FDA clearance to begin a phase 2 trial of Lucid-MS"

A phase 2 trial is an intermediate-stage clinical study that tests whether a new treatment works and is reasonably safe in a group of patients who have the condition it targets. Think of it as a field test of a prototype product: it checks real-world effectiveness and side effects on a modest number of users to decide whether the treatment should move to larger, definitive testing. Investors watch phase 2 results because positive outcomes can sharply increase the likelihood of regulatory approval and future sales, while failures often halt development.

myelin sheath medical

"protecting and potentially repairing the myelin sheath itself"

A myelin sheath is the insulating layer that wraps around nerve fibers, like plastic coating around electrical wiring, allowing the brain and body to send signals quickly and efficiently. It matters to investors because damage or loss of this insulation underlies serious neurological conditions and drives demand for diagnostics, drugs and devices aimed at protecting or repairing myelin, which can influence clinical trial outcomes, regulatory approval prospects and commercial value.

new chemical entity regulatory

"Lucid-MS is a patented new chemical entity shown to prevent"

A new chemical entity (NCE) is a drug whose active ingredient has never been previously approved or marketed; it’s a wholly new molecule rather than a new use of an existing compound. For investors, NCEs matter because they offer fresh commercial opportunities, potential patent and regulatory exclusivity, and correspondingly higher upside if successful — but they also carry greater development and regulatory risk, like betting on an untested recipe.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

To view the full publication, “A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach,” please visit: https://ibn.fm/b9zkB

Multiple sclerosis (“MS”) drugs on the market today can slow the disease down, but none of them stop it, and none of them give patients back what they have already lost. Nearly one million people in the United States, and close to 2.9 million worldwide, live with that reality, watching a disease that can gradually erode mobility, vision and basic bodily control.

That gap has just gotten a serious new challenger. Quantum BioPharma Ltd. has received FDA clearance to begin a phase 2 trial of Lucid-MS, a patented, first-in-class drug candidate aimed not at calming the immune system but at protecting and potentially repairing the myelin sheath itself. The clearance sets the stage for what would be the first time in history that a drug candidate built on this specific mechanism is tested in people living with the MS disease, a milestone significant enough that it has already drawn a fresh buy rating from Wall Street analysts.

About Quantum BioPharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD(TM) and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

For further information, please visit the company’s website at www.QuantumBioPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

DISCLAIMER: BioMedWire (BMW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by BMW are solely those of BMW. Readers of this Article and content agree that they cannot and will not seek to hold liable BMW for any investment decisions by their readers or subscribers. BMW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, BMW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

BMW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BMW undertakes no obligation to update such statements.

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

FAQ

What is Lucid-MS and how does it differ from existing MS treatments?

Lucid-MS is described as a patented, first-in-class new chemical entity that targets the myelin sheath. Instead of calming the immune system like current MS drugs, it is aimed at protecting and potentially repairing myelin. In preclinical models, Lucid-MS has been shown to prevent and reverse myelin degradation, which is the underlying mechanism of multiple sclerosis.

What role does Lucid Psycheceuticals play in Quantum BioPharma’s pipeline?

Lucid Psycheceuticals is a wholly owned subsidiary of Quantum BioPharma that focuses on research and development of the lead compound Lucid-MS. The subsidiary is dedicated to advancing this candidate within Quantum’s broader portfolio targeting neurodegenerative, metabolic and alcohol misuse disorders.

How is Quantum BioPharma economically linked to UNBUZZD(TM)?

Quantum invented UNBUZZD(TM) and spun out its OTC version to Unbuzzd Wellness (formerly Celly Nutrition Corp.). Quantum retains 19.84% ownership in Unbuzzd as of March 31, 2026, and is entitled to a 7% royalty on unbuzzd(TM) sales until cumulative payments reach $250 million. After that threshold, the royalty rate decreases to 3% in perpetuity. Quantum also keeps 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.